Navigation Links
Royalty Pharma Announces Offer May Lapse (Be Withdrawn)
Date:6/13/2013

NEW YORK, June 13, 2013 /PRNewswire/ -- Royalty Pharma today announces that as of 5:30 pm EDT on Wednesday, June 12, 2013 holders of approximately 276 million Elan ADSs (NYSE: ELN), representing more than 70% of the Elan ADSs held in street name, had voted on the Elan proposals.  Based on its review of those votes, Royalty Pharma currently believes that Item 4 - Share Repurchase Program will be approved.  However, Royalty Pharma believes that this proposal can still be voted down if a few shareholders change their vote. Royalty Pharma remains in active dialogue with Elan Shareholders.

The Irish Takeover Panel is requiring Royalty Pharma to lapse (withdraw) its Further Increased Offer even if only the Share Repurchase Program or the ELND005 Transaction is approved at the Elan EGM on 17 June 2013.  Because it does not wish to lapse its offer if only the Share Repurchase Program and / or the ELND005 Transaction are approved, Royalty Pharma is seeking judicial review of this decision of the Irish Takeover Panel, but there can be no assurance that such judicial review will result in any change to that decision. 

Accordingly, Elan shareholders should be aware that:

  • Royalty Pharma's offer may lapse (be withdrawn) as early as Monday, June 17.
  • If Royalty Pharma's offer lapses (is withdrawn), Irish Takeover Rules may prevent Royalty Pharma from making another unsolicited offer for 12 months.

IF YOU HAVE VOTED IN FAVOR OF ITEM 4 - SHARE REPURCHASE PROGRAM BUT WANT ROYALTY PHARMA'S OFFER FOR ELAN TO CONTINUE, YOU ARE URGED TO CHANGE YOUR VOTE TO "AGAINST". 

IF YOU HAVE NOT VOTED, YOU ARE URGED TO VOTE "AGAINST" ALL FOUR RESOLUTIONS PROPOSED BY ELAN AT ITS UPCOMING EGM ON 17 JUNE 2013, INCLUDING THE ELND005 TRANSACTION AND THE S
'/>"/>

SOURCE Royalty Pharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. PDL BioPharma Provides Second Quarter 2013 Royalty Revenue Guidance of $143 Million
2. Royalty Pharma Files Judicial Review Proceedings
3. Royalty Pharma Posts Investor Presentation Summarizing Further Increased Offer For Elan
4. Royalty Pharma Statement Regarding Withdrawal of Elan Lawsuit
5. Royalty Pharma Urges Elan Shareholders to Vote AGAINST ALL FOUR Elan Resolutions Today
6. Royalty Pharma Acceptances Announcement
7. Royalty Pharma Responds To Elans Tysabri Valuation
8. Royalty Pharma Response To Elans "Categorical View On Value"
9. Royalty Pharma Recommends Elan Shareholders vote "NO" on each of the Elan Resolutions at the Elan extraordinary general meeting
10. Royalty Pharma Issues Investor Presentation Highlighting The Strategic And Financial Advantages Of Its Offer To Acquire Elan For $12.50 Per Share In Cash
11. Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... July 6, 2015  EndoChoice Holdings, Inc. (NYSE:  GI) ... 2015 financial results on Thursday, August 6, 2015 before ... a conference call on Thursday, August 6, 2015 at ... numbers are (866) 807-9684 for domestic callers and (412) ... conference call will be available on the investor relations ...
(Date:7/6/2015)... Canadian Pharmacists Association (CPhA) urges the federal government to ... Canadians have the opportunity to protect themselves against the ... lack of access to HPV vaccination programs for young ... putting the health of Canadians at risk. ... a significant threat to the health of Canadians," said ...
(Date:7/6/2015)... Canada , July 6, 2015 ... government initiatives to drive bioinformatics market in ... to a recently released TechSci Research report, " Germany ... in Germany is projected to ... market is expected to witness tremendous growth on account ...
Breaking Medicine Technology:EndoChoice to Report Second Quarter 2015 Financial Results on August 6, 2015 2CPhA Calls for HPV Strategy for Young Men to Save Lives 2Germany Bioinformatics Market to Grow at a CAGR Over 29% Through 2020 Says TechSci Research 2Germany Bioinformatics Market to Grow at a CAGR Over 29% Through 2020 Says TechSci Research 3
... Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ), ... human disease, announced today that results from the Phase ... with non-constipating irritable bowel syndrome (IBS) were published earlier ... journal Gastroenterology .  The issue also included an ...
... National Minority Quality Forum Issue Brief (Specialty Tiering: ... Puckrein and Gretchen Wartman examine specialty tiering, ... as a benefit-management tool to limit their financial exposure ... prescription drugs. The authors remind us that, the Institute ...
Cached Medicine Technology:Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology 2Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology 3Prescription-Drug Plans' Use of Specialty Tiers Promotes Inequalities 2
(Date:7/7/2015)... ... July 07, 2015 , ... ... the launch of their new website, the Invokana Ketoacidosis Lawsuit Center . ... and serves as a resource for persons wishing to learn more about Invokana ...
(Date:7/7/2015)... ... 2015 , ... Clarion Safety Systems , a leading ... the latest issue of In Compliance Magazine, a leading source for news, information ... latest news, standards updates, technical explanations and guidance, as a resource for engineers ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... patient advocate, will be recognized by the White House as a “Champion of ... newly-launched President’s Precision Medicine Initiative, the Champions of Change program recognizes Gleason and ...
(Date:7/7/2015)... Long Island, New York (PRWEB) , ... July 07, 2015 , ... ... services to a wide array of charitable organizations on a local, national and international ... to benefit an organization they believe will have a high impact on the beneficiaries. ...
(Date:7/6/2015)... , ... July 07, 2015 , ... ... in vitro universe. Increasing incidence of AIDS, advances in the molecular diagnostic technologies, ... driving forces. Recent advances in detection technologies and genetic engineering also open lucrative ...
Breaking Medicine News(10 mins):Health News:National Attorneys Launch Invokana Ketoacidosis Lawsuit Center 2Health News:National Attorneys Launch Invokana Ketoacidosis Lawsuit Center 3Health News:Standards Considerations for Laser Safety Labels from Clarion Safety Systems Featured in In Compliance Magazine 2Health News:Standards Considerations for Laser Safety Labels from Clarion Safety Systems Featured in In Compliance Magazine 3Health News:Standards Considerations for Laser Safety Labels from Clarion Safety Systems Featured in In Compliance Magazine 4Health News:White House names Champions of Change for Precision Medicine: CareSync COO Recognized 2Health News:White House names Champions of Change for Precision Medicine: CareSync COO Recognized 3Health News:The Holiday Inn Westbury - Long Island Will Host a Fundraising Event on September 16th 2015 from 6:00 pm - 10:00 pm to Benefit Angela's House located on Long Island 2Health News:The Holiday Inn Westbury - Long Island Will Host a Fundraising Event on September 16th 2015 from 6:00 pm - 10:00 pm to Benefit Angela's House located on Long Island 3Health News:World Infectious Disease Testing Market Examined by VPGMarketResearch.com in In-Demand Report Available at MarketPublishers.com 2Health News:World Infectious Disease Testing Market Examined by VPGMarketResearch.com in In-Demand Report Available at MarketPublishers.com 3
... a pre-emptive move, Rhode Island officials declared holiday for schools ... meningitis/encephalitis outbreak//, after the death of a student to encephalitis ... the state's Public Health Department , said, "Given the parents' ... of caution we would keep schools closed for the next ...
... use of the antiviral Tamiflu to fight pandemic avian ... of what public health officials hope// to avoid––drug-resistant strains ... the Centre for Ecology and Hydrology in Oxford have ... Health Perspectives (EHP) that demonstrate how Tamiflu’s persistence in ...
... availability of new antibacterial hand washing products, plain soap and ... a study published// in the Harvard Health Letter. ... gels might be used as a supplement but not as ... ,The studies shows that washing hands with ...
... more to it than what meets the eye. The young ... marriage// according to the findings of the Social Assessment of ... about HIV/AIDS and protective measures, with girls scoring highest in ... the sexes, boys were seen to be more sexually active; ...
... in the news for the wrong reasons, witnessing an upsurge ... workers is that many women, just barely// twenty years old ... shopping malls. There is an apparent lack of awareness in ... ,When questioned, some of the shopkeepers and salesmen ...
... Midlands, UK, will be dishing out 7000 pounds by way ... sale a magic cream supposed// to cure skin diseases. ... contain Clobetasol Propionate, a prescription steroid drug, used to treat ... Medicines and Healthcare Products Regulatory Agency (MHRA- a government watchdog ...
Cached Medicine News:Health News:Ramifications of Widespread Use of Tamiflu 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: